Search results
Results from the WOW.Com Content Network
This is a list of investigational antidepressants, or drugs that are currently under development for clinical use in the treatment of depression but are not yet approved. Specific indications include major depressive disorder , treatment-resistant depression , dysthymia , bipolar depression , and postpartum depression , among others.
This is a complete list of clinically approved prescription antidepressants throughout the world, as well as clinically approved prescription drugs used to augment antidepressants or mood stabilizers, by pharmacological and/or structural classification. Chemical/generic names are listed first, with brand names in parentheses.
These are lists of investigational drugs: List of investigational analgesics; List of investigational antidepressants; List of investigational antipsychotics; List of investigational anxiolytics; List of investigational attention deficit hyperactivity disorder drugs; List of investigational autism and pervasive developmental disorder drugs
This page was last edited on 3 December 2023, at 22:17 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
NV-5138 also known as SPN-820 is an investigational new drug that is being evaluated by Navitor Pharmaceuticals and Supernus Pharmaceuticals [2] for the treatment of major depressive disorder (MDD). [3] [1] [4] [5]
It should only contain pages that are antidepressants or lists of antidepressants, as well as subcategories containing those things (themselves set categories). Topics about antidepressants in general should be placed in relevant topic categories .
Rapastinel (INN Tooltip International Nonproprietary Name) (former developmental code name GLYX-13) is a novel antidepressant that was under development by Allergan (previously Naurex) as an adjunctive therapy for the treatment of treatment-resistant depression.
This is a list of investigational social anxiety disorder drugs, or drugs that are currently under development for clinical use in the treatment of social anxiety disorder (SAD; or social phobia) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.